It seems prudent now to consider SCRMS to be two prognostically and biologically separate subtypes of rhabdomyosarcoma, much as ERMS andPAX-FOXO1 fusion-positive alveolar RMS have become. This evidence concerns the gene FOXO1 and rhabdomyosarcoma.